Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...

In mid-2024, the Company initiated once daily dosing of ORIC-944 in combination with 240 mg QD apalutamide or with 600 mg BID darolutamide, as part of the ongoing Phase 1b trial in patients with ...

Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains ...

They can now choose among 4 novel second-generation hormone therapies (the androgen receptor pathway inhibitors [ARPIs] abiraterone, enzalutamide, apalutamide, and darolutamide), 2 chemotherapy ...

The man's PSA was recorded at 1.09 ng/mL. As the findings were "suggestive of disease progression", doctors began treating him with apalutamide, a type of hormone therapy used to treat prostate ...

as well as cancer drug Erleada (apalutamide) and Stelara follow-up Tremfya (guselkumab). Chief executive Joaquin Duato said that J&J has a "strong foundation for near and long-term growth", thanks ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul ...